Immuron (IMRN) Net Income towards Common Stockholders (2016 - 2024)
Immuron (IMRN) recorded quarterly Net Income towards Common Stockholders of $1660259165.7 billion in Q4 2024, up 80082653894884.78% quarter-over-quarter from -$2.1 million in Q4 2023, and up 80082653894884.8% on a YoY basis from N/an in Q1 2024.
Immuron (IMRN) Net Income towards Common Stockholders (2016 - 2024) Analysis & Trends
Immuron's Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at $1660259165.7 billion for Q4 2024.
- In Q4 2024, Net Income towards Common Stockholders rose 80082653894884.8% year-over-year to $1660259165.7 billion; the TTM figure through Sep 2025 stood at $1660259165.7 billion (up 470814844753249.8% YoY), while the FY2025 annual figure was -$3.4 million, up 25.69% from the prior year.
- Net Income towards Common Stockholders was $1660259165.7 billion for Q4 2024 at Immuron, up from -$2.1 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $1660259165.7 billion in Q4 2024 to a low of -$2.1 million in Q4 2023.
- Historically, Net Income towards Common Stockholders has averaged $237179880.8 billion across 5 years, with a median of -$13260.2 in 2021.
- The sharpest annual moves came in 2020 and 2024: Net Income towards Common Stockholders plunged 277.25% in 2020, then jumped 80082653894884.8% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$57387.7 in 2020, then soared by 76.89% to -$13260.2 in 2021, then surged by 13879.86% to $1.8 million in 2022, then sank by 213.46% to -$2.1 million in 2023, then surged by 80082653894884.78% to $1660259165.7 billion in 2024.
- The last three Net Income towards Common Stockholders figures came in at $1660259165.7 billion (Q4 2024), -$2.1 million (Q4 2023), and $2.4 million (Q3 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Immuron | 921.61 Mn | 921.58 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1,660,259,165.67 Bn |
| Dec 31, 2023 | -2.07 Mn |
| Sep 28, 2023 | 2.43 Mn |
| Jun 30, 2023 | -1.24 Mn |
| Dec 31, 2022 | 1.83 Mn |
| Dec 31, 2021 | -13,260.17 |
| Dec 31, 2020 | -57,387.72 |
| Dec 31, 2019 | -15,212.27 |
| Dec 31, 2018 | -1.58 Mn |
| Dec 31, 2017 | 3.84 Mn |
| Dec 31, 2016 | 2.56 Mn |
| Jun 30, 2016 | -3.28 Mn |